Corporate Presentation
Obesity
Dapiglutide
Dapiglutide showed dose-dependent mean weight loss
of up to 4.3% over 4 weeks in healthy patients
Phase 1 multiple ascending dose trial (n=40)
ZEAL&
ZEALAND PHARMA
2
0
Placebo
(n=12)
Change in body weight (%)
+
Dapiglutide
1.0 mg (n=7)
Dapiglutide
2.25 mg (n=7)
Dapiglutide
3.5 mg (n=7)
Dapiglutide
3.5/6.0 mg (n=7)
Mean relative
change at Week 4:
-4.3%
-6.
T
0 1
2
3
401
2
T
3
T
2
3
Dosing
T
T
T
T
401
2
3 401 2 3
4 0 1
Weeks from first dose
Dapiglutide was generally well-tolerated with no severe or serious AEs,
no withdrawals due to AEs, and no observation of anti-drug antibodies
Source: Figures adapted from data presented by Agersnap at the 82nd ADA Scientific Sessions, June 3-7, 2022, New Orleans, LA.
AE=adverse event.
21
24View entire presentation